Frank Watanabe is the founder of Arcutis Biotherapeutics. Arcutis Biotherapeutics has raised $160M in total funding. Latest round: IPO.
Frank Watanabe is the President and CEO of Arcutis Biotherapeutics, a public biopharmaceutical company focused on developing treatments for immune-mediated dermatological diseases. He has held the CEO position since 2017 and President since 2016. Arcutis was founded in 2016 and went public on NASDAQ in January 2020. Prior to Arcutis, Watanabe co-founded Kanan Therapeutics and held executive roles at Kythera Biopharmaceuticals and Amgen, Inc.
Full founder directory · Investor directory · Company funding database · Fundraising library